Lipocine Inc. (LPCN)
Lipocine Announces Completion of Enrollment and Dosing in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)
Lipocine Announces Completion of Enrollment and Dosing in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)
📈 **POSITIVE** • Medium confidence analysis (69%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business